In vivo evolution of ceftazidime-avibactam resistance in bla OXA-244-positive E. coli potentially linked to PBP3 insertion and mutations in acrB and PBP2.

IF 3.3 Q2 INFECTIOUS DISEASES
Kaan Kocer, Sébastien Boutin, Guido Hansen, Dennis Nurjadi, Niklas Maximilian Weidner
{"title":"<i>In vivo</i> evolution of ceftazidime-avibactam resistance in <i>bla</i> <sub>OXA-244</sub>-positive <i>E. coli</i> potentially linked to PBP3 insertion and mutations in <i>acrB</i> and PBP2.","authors":"Kaan Kocer, Sébastien Boutin, Guido Hansen, Dennis Nurjadi, Niklas Maximilian Weidner","doi":"10.1093/jacamr/dlaf137","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Ceftazidime/avibactam has been introduced as a promising treatment option against multidrug-resistant Gram-negative bacteria.</p><p><strong>Objectives: </strong>To investigate the development of ceftazidime/avibactam resistance in a <i>bla</i> <sub>OXA-48-like</sub>-carrying <i>Escherichia coli</i> strain with YRIK insertion in penicillin-binding protein 3 (PBP3).</p><p><strong>Methods: </strong>Eight clinical isolates were recovered from a single patient treated with ceftazidime/avibactam. The isolates were analysed using antimicrobial susceptibility testing, and WGS to identify potential resistance mechanisms. <i>In vitro</i> serial passage experiments with increasing ceftazidime/avibactam exposure were performed to model the <i>in vivo</i> resistance development. Quantitative RT-PCR was used to assess <i>acrB</i> mRNA expression.</p><p><strong>Results: </strong>Ceftazidime/avibactam resistance emerged during treatment, accompanied by significant increases in aztreonam/avibactam and avibactam MICs. All isolates, including those susceptible to ceftazidime/avibactam, had a YRIK insertion in PBP3. Additional mutations were identified in the AcrB efflux pump component and, in most cases in its regulatory genes and PBP2 in the resistant isolates. No significant differences in <i>acrB</i> expression levels were found between susceptible and resistant isolates, suggesting that structural changes in AcrB, rather than overexpression, are likely to contribute to resistance. Serial passage experiments confirmed these findings by demonstrating the emergence of mutations in the same genes under increasing ceftazidime/avibactam pressure.</p><p><strong>Conclusions: </strong>This study shows a complex resistance mechanism involving a YRIK insertion in PBP3, combined with mutations in AcrB and PBP2, as drivers of ceftazidime/avibactam resistance. These findings highlight the importance of monitoring <i>E. coli</i> isolates with YRIK insertions during ceftazidime/avibactam treatment and warrant further investigation into efflux pump-mediated resistance in Enterobacterales.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"7 4","pages":"dlaf137"},"PeriodicalIF":3.3000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314485/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAC-Antimicrobial Resistance","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jacamr/dlaf137","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Ceftazidime/avibactam has been introduced as a promising treatment option against multidrug-resistant Gram-negative bacteria.

Objectives: To investigate the development of ceftazidime/avibactam resistance in a bla OXA-48-like-carrying Escherichia coli strain with YRIK insertion in penicillin-binding protein 3 (PBP3).

Methods: Eight clinical isolates were recovered from a single patient treated with ceftazidime/avibactam. The isolates were analysed using antimicrobial susceptibility testing, and WGS to identify potential resistance mechanisms. In vitro serial passage experiments with increasing ceftazidime/avibactam exposure were performed to model the in vivo resistance development. Quantitative RT-PCR was used to assess acrB mRNA expression.

Results: Ceftazidime/avibactam resistance emerged during treatment, accompanied by significant increases in aztreonam/avibactam and avibactam MICs. All isolates, including those susceptible to ceftazidime/avibactam, had a YRIK insertion in PBP3. Additional mutations were identified in the AcrB efflux pump component and, in most cases in its regulatory genes and PBP2 in the resistant isolates. No significant differences in acrB expression levels were found between susceptible and resistant isolates, suggesting that structural changes in AcrB, rather than overexpression, are likely to contribute to resistance. Serial passage experiments confirmed these findings by demonstrating the emergence of mutations in the same genes under increasing ceftazidime/avibactam pressure.

Conclusions: This study shows a complex resistance mechanism involving a YRIK insertion in PBP3, combined with mutations in AcrB and PBP2, as drivers of ceftazidime/avibactam resistance. These findings highlight the importance of monitoring E. coli isolates with YRIK insertions during ceftazidime/avibactam treatment and warrant further investigation into efflux pump-mediated resistance in Enterobacterales.

Abstract Image

Abstract Image

bla oxa -244阳性大肠杆菌对头孢他啶-阿维巴坦耐药的体内进化可能与PBP3插入和acrB和PBP2突变有关。
背景:头孢他啶/阿维巴坦作为一种治疗多重耐药革兰氏阴性菌的有希望的选择已被引入。目的:探讨携带bla oxa -48样、YRIK插入青霉素结合蛋白3 (PBP3)的大肠埃希菌对头孢他啶/阿维巴坦耐药的进展。方法:从头孢他啶/阿维巴坦治疗的1例患者中分离出8株临床分离株。采用药敏试验和WGS分析分离菌株的潜在耐药机制。通过增加头孢他啶/阿维巴坦暴露量的体外连续传代实验来模拟体内耐药性的发展。采用定量RT-PCR检测acrB mRNA表达。结果:治疗期间出现头孢他啶/阿维巴坦耐药,同时伴有氨曲南/阿维巴坦和阿维巴坦mic显著升高。所有分离株,包括对头孢他啶/阿维巴坦敏感的分离株,在PBP3中都有YRIK插入。在耐药菌株的AcrB外排泵成分中发现了额外的突变,在大多数情况下在其调控基因和PBP2中发现了突变。在易感菌株和耐药菌株之间,acrB的表达水平没有显著差异,这表明acrB的结构变化,而不是过表达,可能导致耐药。连续传代实验证实了这些发现,表明在增加头孢他啶/阿维巴坦压力下,相同基因出现突变。结论:本研究显示了一个复杂的耐药机制,包括YRIK插入PBP3,结合AcrB和PBP2突变,作为头孢他啶/阿维巴坦耐药的驱动因素。这些发现强调了在头孢他啶/阿维巴坦治疗期间监测含有YRIK插入的大肠杆菌分离株的重要性,并为进一步研究肠杆菌外排泵介导的耐药性提供了依据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.30
自引率
0.00%
发文量
0
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信